Healthcare Industry News: arrhythmia
News Release - June 25, 2015
Spacelabs Reinvents Medical Telemetry with Release of XTR
SNOQUALMIE, Wash.--(Healthcare Sales & Marketing Network)--Spacelabs Healthcare today announced the release of the newest medical telemetry solution on the market – XTR – Xhibit Telemetry.As the original innovators of telemetry with roots in the NASA space program, Spacelabs’ latest telemetry system offers a simple workflow for managing patients, intelligent arrhythmia analysis, and advanced alarm management.
XTR’s real-time arrhythmia algorithms capture seven leads of ECG, all viewable from the central station, where the three best leads analyze arrhythmia using dedicated wireless medical telemetry bands for superior interpretation of ambulatory patients.
“XTR is the exclamation point to a multi-year comprehensive product update of our entire product family,” said Spacelabs’ President Nicholas Ong. “With the newest end-to-end product line on the market, Spacelabs provides a powerful enterprise solution that isn’t just backwards compatible, but poises the company for more clinical and technical innovations on the horizon.”
XTR is optimized for use with the latest Spacelabs’ products, including:
- Xhibit, a scalable 48 patient central monitoring system, for seamless patient transfer from virtually any bed, anywhere in a hospital.
- Spacelabs Assurance, advanced alarm management software, with tools to help reduce alarm fatigue and optimize patient safety.
- AriaTele, the newest telemetry transmitter, featuring a comprehensive view of all leads and SPo2 with an onboard display right on the transmitter.
XTR is also fully integrated within Clinical Access for a retrospective view from virtually any computer workstation in the hospital, outside of the hospital or with ICS XPREZZ – the IOS Smart disclosure app—available on iTunes.
To learn more and to see a demo of XTR, contact your local sales representative or global distributor.
Source: Spacelabs
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
